Mirum Pharmaceuticals (MIRM) Short term Debt (2020 - 2023)
Historic Short term Debt for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Q1 2023 value amounting to $1.1 million.
- Mirum Pharmaceuticals' Short term Debt fell 4539.08% to $1.1 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.1 million, marking a year-over-year decrease of 4539.08%. This contributed to the annual value of $1.1 million for FY2022, which is 4539.08% down from last year.
- As of Q1 2023, Mirum Pharmaceuticals' Short term Debt stood at $1.1 million, which was down 4539.08% from $1.1 million recorded in Q4 2022.
- Mirum Pharmaceuticals' Short term Debt's 5-year high stood at $2.2 million during Q2 2021, with a 5-year trough of $847000.0 in Q3 2021.
- Over the past 4 years, Mirum Pharmaceuticals' median Short term Debt value was $1.5 million (recorded in 2020), while the average stood at $1.5 million.
- Data for Mirum Pharmaceuticals' Short term Debt shows a peak YoY increase of 11462.37% (in 2022) and a maximum YoY decrease of 4539.08% (in 2022) over the last 5 years.
- Over the past 4 years, Mirum Pharmaceuticals' Short term Debt (Quarter) stood at $1.3 million in 2020, then soared by 57.91% to $2.0 million in 2021, then crashed by 45.39% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023.
- Its Short term Debt was $1.1 million in Q1 2023, compared to $1.1 million in Q4 2022 and $1.8 million in Q3 2022.